Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.

Maust JD, Frankowski-McGregor CL, Bankhead A 3rd, Simeone DM, Sebolt-Leopold JS.

Mol Cancer Ther. 2018 Dec;17(12):2495-2506. doi: 10.1158/1535-7163.MCT-18-0082. Epub 2018 Sep 25.

PMID:
30254182
2.

Development of Preclinical Models to Understand and Treat Colorectal Cancer.

Sebolt-Leopold JS.

Clin Colon Rectal Surg. 2018 May;31(3):199-204. doi: 10.1055/s-0037-1602240. Epub 2018 Apr 1. Review.

3.

Oncogenic Mutants of MEK1: A Trilogy Unfolds.

Maust JD, Whitehead CE, Sebolt-Leopold JS.

Cancer Discov. 2018 May;8(5):534-536. doi: 10.1158/2159-8290.CD-18-0192.

4.

Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor.

Ramkumar K, Samanta S, Kyani A, Yang S, Tamura S, Ziemke E, Stuckey JA, Li S, Chinnaswamy K, Otake H, Debnath B, Yarovenko V, Sebolt-Leopold JS, Ljungman M, Neamati N.

Nat Commun. 2016 Oct 5;7:13084. doi: 10.1038/ncomms13084.

5.

Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.

Zhang H, Ramakrishnan SK, Triner D, Centofanti B, Maitra D, Győrffy B, Sebolt-Leopold JS, Dame MK, Varani J, Brenner DE, Fearon ER, Omary MB, Shah YM.

Sci Signal. 2015 Oct 6;8(397):ra98. doi: 10.1126/scisignal.aac5418.

6.

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS.

Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14.

7.

Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.

Dosch JS, Ziemke EK, Shettigar A, Rehemtulla A, Sebolt-Leopold JS.

Cancer Res. 2015 Nov 1;75(21):4582-92. doi: 10.1158/0008-5472.CAN-14-2793. Epub 2015 Sep 10.

8.

ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.

Holtz BJ, Lodewyk KB, Sebolt-Leopold JS, Ernst SA, Williams JA.

Am J Physiol Gastrointest Liver Physiol. 2014 Oct 1;307(7):G700-10. doi: 10.1152/ajpgi.00163.2014. Epub 2014 Aug 7.

9.

MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.

Collins MA, Yan W, Sebolt-Leopold JS, Pasca di Magliano M.

Gastroenterology. 2014 Mar;146(3):822-834.e7. doi: 10.1053/j.gastro.2013.11.052. Epub 2013 Dec 6.

10.

Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.

Galbán CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Galbán S, Sebolt-Leopold JS, Rehemtulla A, Ross BD.

Clin Cancer Res. 2011 Jul 15;17(14):4751-60. doi: 10.1158/1078-0432.CCR-10-2098. Epub 2011 Apr 28.

11.

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.

Sebolt-Leopold JS.

Clin Cancer Res. 2008 Jun 15;14(12):3651-6. doi: 10.1158/1078-0432.CCR-08-0333.

12.

4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

Spicer JA, Rewcastle GW, Kaufman MD, Black SL, Plummer MS, Denny WA, Quin J 3rd, Shahripour AB, Barrett SD, Whitehead CE, Milbank JB, Ohren JF, Gowan RC, Omer C, Camp HS, Esmaeil N, Moore K, Sebolt-Leopold JS, Pryzbranowski S, Merriman RL, Ortwine DF, Warmus JS, Flamme CM, Pavlovsky AG, Tecle H.

J Med Chem. 2007 Oct 18;50(21):5090-102. Epub 2007 Sep 19.

PMID:
17880056
13.

The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment.

Sebolt-Leopold JS, Herrera R, Ohren JF.

Recent Results Cancer Res. 2007;172:155-67. Review. No abstract available.

PMID:
17607940
14.

Mechanisms of drug inhibition of signalling molecules.

Sebolt-Leopold JS, English JM.

Nature. 2006 May 25;441(7092):457-62. Review.

PMID:
16724058
15.

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS.

Neoplasia. 2006 Jan;8(1):1-8.

16.

Inhibitors of Bcr-abl... breaking new ground again.

Ohren JF, Sebolt-Leopold JS.

Nat Chem Biol. 2006 Feb;2(2):63-4. No abstract available.

PMID:
16421581
17.

Targeting the mitogen-activated protein kinase cascade to treat cancer.

Sebolt-Leopold JS, Herrera R.

Nat Rev Cancer. 2004 Dec;4(12):937-47. Review.

PMID:
15573115
18.

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB.

J Clin Oncol. 2004 Nov 15;22(22):4456-62. Epub 2004 Oct 13.

PMID:
15483017
19.

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.

Sebolt-Leopold JS.

Curr Pharm Des. 2004;10(16):1907-14. Review.

PMID:
15180527
20.

Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition.

Sebolt-Leopold JS, Van Becelaere K, Hook K, Herrera R.

Methods Mol Med. 2003;85:31-8. Review. No abstract available.

PMID:
12710194
21.

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.

Herrera R, Sebolt-Leopold JS.

Trends Mol Med. 2002;8(4 Suppl):S27-31. Review. Erratum in: Trends Mol Med 2002 May;8(5):243.

PMID:
11927284
22.

Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms.

Gibbs RA, Zahn TJ, Sebolt-Leopold JS.

Curr Med Chem. 2001 Oct;8(12):1437-65. Review.

PMID:
11562276
23.

Development of anticancer drugs targeting the MAP kinase pathway.

Sebolt-Leopold JS.

Oncogene. 2000 Dec 27;19(56):6594-9. Review.

24.

Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation.

Gibbs BS, Zahn TJ, Mu Y, Sebolt-Leopold JS, Gibbs RA.

J Med Chem. 1999 Sep 23;42(19):3800-8.

PMID:
10508429
25.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.

Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR.

Nat Med. 1999 Jul;5(7):810-6.

PMID:
10395327
26.

Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors.

Eummer JT, Gibbs BS, Zahn TJ, Sebolt-Leopold JS, Gibbs RA.

Bioorg Med Chem. 1999 Feb;7(2):241-50.

PMID:
10218815
27.

Protein prenylation: from discovery to prospects for cancer treatment.

Gelb MH, Scholten JD, Sebolt-Leopold JS.

Curr Opin Chem Biol. 1998 Feb;2(1):40-8. Review.

PMID:
9667914
28.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

McNamara DJ, Dobrusin E, Leonard DM, Shuler KR, Kaltenbronn JS, Quin J 3rd, Bur S, Thomas CE, Doherty AM, Scholten JD, Zimmerman KK, Gibbs BS, Gowan RC, Latash MP, Leopold WR, Przybranowski SA, Sebolt-Leopold JS.

J Med Chem. 1997 Oct 10;40(21):3319-22. No abstract available.

PMID:
9341905
29.

Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.

Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Sawyer TK, Hodges JC, Su TZ, Scholten JD, Gowan RC, Sebolt-Leopold JS, Doherty AM.

J Med Chem. 1997 Jan 17;40(2):192-200.

PMID:
9003517
30.

Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.

Horwitz JP, Massova I, Wiese TE, Wozniak AJ, Corbett TH, Sebolt-Leopold JS, Capps DB, Leopold WR.

J Med Chem. 1993 Nov 12;36(23):3511-6.

PMID:
8280289
31.

Enhancement of alkylating agent activity in vitro by PD 128763, a potent poly(ADP-ribose) synthetase inhibitor.

Sebolt-Leopold JS, Scavone SV.

Int J Radiat Oncol Biol Phys. 1992;22(3):619-21.

PMID:
1531221
32.

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.

Int J Radiat Oncol Biol Phys. 1992;22(3):549-51.

PMID:
1531213
33.

Synthesis and evaluation of a series of 3,5-disubstituted benzisoxazole-4,7-diones. Potent radiosensitizers in vitro.

Suto MJ, Stier MA, Winters RT, Turner WR, Pinter CD, Elliott WE, Sebolt-Leopold JS.

J Med Chem. 1991 Nov;34(11):3290-4.

PMID:
1956048
34.

A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.

Suto MJ, Stier MA, Werbel LM, Arundel-Suto CM, Leopold WR, Elliott WE, Sebolt-Leopold JS.

J Med Chem. 1991 Aug;34(8):2484-8.

PMID:
1875345
35.

Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells.

Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS.

Radiat Res. 1991 Jun;126(3):367-71.

PMID:
1903547
36.

Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase.

Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM, Sebolt-Leopold JS.

Anticancer Drug Des. 1991 May;6(2):107-17.

PMID:
1903948

Supplemental Content

Loading ...
Support Center